In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018

Liu, Po-YuPo-YuLiuKo, Wen-ChienWen-ChienKoLee, Wen-SenWen-SenLeeLu, Po-LiangPo-LiangLuChen, Yen-HsuYen-HsuChenCheng, Shu-HsingShu-HsingChengLu, Min-ChiMin-ChiLuLin, Chi-YingChi-YingLinWu, Ting-ShuTing-ShuWuYen, Muh-YongMuh-YongYenWang, Lih-ShinnLih-ShinnWangLiu, Chang-PanChang-PanLiuPEI-LAN SHAOLee, Yu-LinYu-LinLeeShi, Zhi-YuanZhi-YuanShiChen, Yao-ShenYao-ShenChenWang, Fu-DerFu-DerWangTseng, Shu-HuiShu-HuiTsengLin, Chao-NanChao-NanLinChen, Yu-HuiYu-HuiChenWANG-HUEI SHENGLee, Chun-MingChun-MingLeeTang, Hung-JenHung-JenTangPO-REN HSUEH2022-04-282022-04-282021-09-0416841182https://scholars.lib.ntu.edu.tw/handle/123456789/608273This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics.enCefepime/enmetazobactam; Cefepime/zidebactam; Cefiderocol; Eravacycline; OmadacyclineIn vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020journal article10.1016/j.jmii.2021.08.012345215912-s2.0-85114724226https://scholars.lib.ntu.edu.tw/handle/123456789/588107